Provided by Tiger Trade Technology Pte. Ltd.

Xeris Pharmaceuticals Inc

6.05
+0.01000.17%
Post-market: 6.00-0.0500-0.83%19:37 EDT
Volume:893.18K
Turnover:5.43M
Market Cap:1.04B
PE:1.89K
High:6.15
Open:6.04
Low:5.97
Close:6.04
52wk High:10.08
52wk Low:3.81
Shares:172.43M
Float Shares:159.00M
Volume Ratio:0.47
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0032
EPS(LYR):0.0032
ROE:-617.16%
ROA:4.40%
PB:76.21
PE(LYR):1,886.50

Loading ...

BRIEF-Xeris Biopharma Subsidiaries File Recorlev Patent Infringement Lawsuit

Reuters
·
Feb 27

Xeris Biopharma Subsidiaries Sue Torrent and Somerset Over Recorlev Patents Through 2040

Reuters
·
Feb 27

Xeris Biopharma Holdings Inc: Intends to Enforce and Defend Its Intellectual Property Rights Relating to Recorlev

THOMSON REUTERS
·
Feb 27

Earning Preview: Xeris Pharmaceuticals Inc Q1 revenue is expected to increase by 41.71%, and institutional views are constructive

Earnings Agent
·
Feb 23

Xeris Biopharma Holdings Inc. published an update to their financial calendar

Reuters
·
Feb 17

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

THOMSON REUTERS
·
Feb 17

A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Updated 2025 Revenue Outlook

Simply Wall St.
·
Jan 18

Xeris Biopharma President and COO Kevin McCulloch Reports Disposal of Common Shares

Reuters
·
Jan 10

Xeris Biopharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 09

Xeris Biopharma Expects 2025 Revenue to Reach $292 Million

Reuters
·
Jan 08

Xeris Biopharma Holdings Inc - Expects 2025 Revenue of $292 Mln, Exceeding Guidance

THOMSON REUTERS
·
Jan 08

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

THOMSON REUTERS
·
Jan 08

Xeris Biopharma Holdings Inc. Officer John Patrick Shannon Jr. Reports Disposal of Common Shares

Reuters
·
Jan 07

Xeris Biopharma Officer Beth Hecht Reports Sale of Common Shares

Reuters
·
Jan 06

BRIEF-Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jan 03

Xeris Biopharma Grants 181,550 Restricted Stock Units to New Employees

Reuters
·
Jan 03

Have Xeris Biopharma Holdings Insiders Been Selling Stock?

Simply Wall St.
·
Dec 22, 2025

Director John Johnson Reports Sale of Xeris Biopharma Holdings Inc. Common Shares

Reuters
·
Dec 20, 2025

Director Barbara-Jean Anne Bormann-Kennedy Sells Xeris Biopharma Holdings Inc. Common Shares

Reuters
·
Dec 16, 2025

Xeris Biopharma Initiated at Overweight by Barclays

Dow Jones
·
Dec 10, 2025